Breaking up is hard to do: Lessons learned from a pharma-free practice transformation

Journal of the American Board of Family Medicine

Volumn 26, Issue 3, 2013, Pages 332-338

  Evans, David ^a   Hartung, Daniel M ^b   Beasley, Denise ^b   Fagnan, Lyle J ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Conflict of Interest; Drug Industry; Medical Ethics; Practice Management

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; DRUG COST; DRUG INDUSTRY; HUMAN; MEDICAL STAFF; PHYSICIAN; PHYSICIAN ASSISTANT; PRIVATE PRACTICE; TOTAL QUALITY MANAGEMENT; UNIVERSITY HOSPITAL;

CONFLICT OF INTEREST; DRUG INDUSTRY; MEDICAL ETHICS; PRACTICE MANAGEMENT;

ATTITUDE OF HEALTH PERSONNEL; CONFLICT OF INTEREST; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; FAMILY PRACTICE; GIFT GIVING; HEALTH CARE REFORM; HEALTH POLICY; HUMANS; INSERVICE TRAINING; MARKETING; OREGON; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE MANAGEMENT, MEDICAL; UNITED STATES;

EID: 84877766899     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2013.03.120268     Document Type: Article

References (27)

1. May CD. Selling drugs by "educating" physicians. J Med Educ 1961;36:1-23.
2. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008;5:e1.
3. IMS Health. Total US promotional spend by type, 2011. Available from http://www.imshealth.com/ deployedfiles/ims/Global/Content/Corporate/Press% 20Room/Top-Line%20Market%20Data%20&% 20Trends/2011%20Top- line%20Market%20Data/ Promo-Spend-By-Type.pdf. Accessed March 26, 2013.
4. Berenson A. Pfizer to cut its U.S. sales force by 20%.New York Times 2009. Available from http://www.nytimes. com/2006/11/28/business/28cnd-pfizer. html?-r=0. Accessed August 6, 2012.
5. GlaxoSmithKline to cut 1,000 sales jobs in the U.S. New York Times 2008. Available from http://www.nytimes.com/2008/11/06/business/06glaxo.html. Accessed August 6, 2012.
6. Blumenthal D. Doctors and drug companies. N Engl J Med 2004;351:1885-90. (Pubitemid 39426325)
7. Bureau of Labor Statistics. Occupational outlook handbook [homepage]. Avaiable from http://www. bls.gov/ooh/. Accessed March 13, 2013.
8. Wazana A. Physicians and the pharmaceutical industry. JAMA 2000;283:373-80.
9. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006;295:429-33. (Pubitemid 43144979)
10. Brody H. The company we keep: why physicians should refuse to see pharmaceutical representatives. Ann Fam Med 2005;3:82-5. (Pubitemid 40203953)
11. Brewer D. The effect of drug sampling policies on residents' prescribing. Fam Med 1998;30: 482-6. (Pubitemid 28331138)
12. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med 2010; 7:e1000352.
13. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007;297:1216-23. (Pubitemid 46469916)
14. Chimonas S, Patterson L, Raveis VH, Rothman DJ. Managing conflicts of interest in clinical care: a national survey of policies at U.S. medical schools. Acad Med 2011;86:293-9.
15. Carpenter D JS. A unique researcher identifier for the physician payments sunshine act. JAMA 2011; 305:2007-8.
16. Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009;301:1367-72.
17. Raad R, Appelbaum PS. Relationships between medicine and industry: approaches to the problem of conflicts of interest. Ann Rev Med 2012;63:465-77.
18. Cohen ML. Taming the sample closet. Fam Pract Manag 2006;13:43-6.
19. Erickson S, Cullison S. Closing the sample closet. Fam Pract Manage 1995;1:43-7.
20. Brown SR. Closing the sample closet. Fam Pract Manag 2006;13:16, author reply 21.
21. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2005.
22. Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, Miralles PD. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med 2010;170:1820-6.
23. Association of American Medical Colleges. Industry funding of medical education. Report of anAAMCtast force. June 2008. Available from https://members. aamc.org/eweb/upload/Industry%20Funding%20of% 20Medical%20Education.pdf. Accessed March 13, 2013.
24. Evans DV, Hartung DM, Andeen G, et al. One practice's experiment in refusing detail rep visits. J Fam Pract 2011;60:E1-6.
25. Avorn J, Fischer M. 'Bench to behavior': translating comparative effectiveness research into improved clinical practice. Health Aff (Millwood) 2010;29: 1891-900.
26. Mitka M. New physician education initiatives seek to remove the devil from the detailing. JAMA 2011; 306:1187-8.
27. Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998;13:151-4. (Pubitemid 28128992)